NORTH LIBERTY, Iowa--(BUSINESS WIRE)--KemPharm, Inc. today announced positive results from a Phase 1 clinical trial of KP106, its novel prodrug for attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of the active pharmaceutical compound d-amphetamine and a ligand, was created using KemPharm’s proprietary Ligand Activated Therapy (LAT) prodrug approach. The pharmacokinetic (PK) profile of d-amphetamine released from KP106 is modified versus the profile observed with Vyvanse®, a currently marketed amphetamine-based stimulant for ADHD. These results suggest that KP106 may have an improved side effect profile and a lower propensity for drug abuse. Most significantly, the data reported from the trial proved that KP106 is cleaved and d-amphetamine is released as predicted in humans; therefore establishing proof of concept for KP106.
